A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Hurwitz, Herbert; Crocenzi, Todd; Lohr, Joanna; Bonvini, Ezio; Johnson, Syd; Moore, Paul; Wigginton, Jon

doi:10.1186/2051-1426-2-S3-P86

Article metrics
Last updated: Sat, 20 Apr 2024 5:46:32 Z

A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART^®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Access & Citations

1319

Article Accesses
0

Web of Science
9

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.